Abstracts Archive - Page 377 of 2425 - ACR Meeting Abstracts

Abstract Number: 1388 • ACR Convergence 2022
Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes
Anthony Dolomisiewicz¹, Hanifah Ali², Punyasha Roul³, Yangyuna Yang¹, Grant Cannon⁴, Joshua Baker⁵, Ted Mikuls⁶, Kaleb Michaud¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, ³UNMC, Omaha, NE, ⁴Salt Lake City VA, Salt Lake city, ⁵University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Rheumatic Disease Comorbidity Index (RDCI) was designed to quantify comorbidity burden for risk stratification of health outcomes in patients with rheumatic disease. Developed…
Abstract Number: 1373 • ACR Convergence 2022
Increased Patient Contact May Mitigate Flares Among jSLE Patients
Jessica Fennell, Deanna Jannat-Khah, DrPH, MSPH and karen onel, Hospital for Special Surgery, New York, NY
Background/Purpose: Optimizing jSLE management is crucial to prevent flares as the damage sustained during flares contributes to lifelong morbidity and mortality. The onset of the…
Abstract Number: 1387 • ACR Convergence 2022
Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe
Ran Jin¹, Megan Hughes², Emily Goddard², James Piercy², Delphine Courmier², Rachael Meadows² and Waldemar Radziszewski¹, ¹Amgen, Inc., Thousand Oaks, CA, ²Adelphi Group, Bollington, United Kingdom
Background/Purpose: ABP 501 is the first adalimumab biosimilar approved by the European Medicines Agency. A clinical trial demonstrated biosimilarity between ABP 501 and the reference…
Abstract Number: 1386 • ACR Convergence 2022
The Association of Depression with Executive Function Skills and Health-Related Quality of Life in Youth with Systemic Lupus Erythematosus
Busisiwe Zapparoli¹, Sarah Mossad¹, Stephanie Fevrier², Victoria Lishak³, Tala El Tal⁴, Lawrence Ng¹, Paris Moaf¹, Joanna Law¹, Ibrahim Mohamed⁵, Linda Hiraki⁶, Deborah Levy⁷, ashley Danguecan¹ and Andrea Knight⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, ON, Canada 3Institute of Biomedical Engineering, University of Toronto, Brampton, ON, Canada, ⁶The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Depression is a frequent symptom in childhood-onset SLE (cSLE), and is likely multifactorial. Executive function (EF) refers to conscious and volitional efforts to regulate…
Abstract Number: 1382 • ACR Convergence 2022
Juvenile Eosinophilic Fasciitis: A Single-Center Cohort
Leigh Stubbs¹, Oluwaseun Ogunbona², Adekunle Adesina¹, Sara Anvari¹, Emily Beil¹, Jamie Lai¹, Andrea Ramirez¹, Vibha Szafron¹, Matthew Ditzler¹ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Houston Methodist Hospital, Houston, TX
Background/Purpose: Eosinophilic fasciitis (EF) is a rare fibrosing disease. Since described in 1975, less than 30 pediatric cases have been reported. EF presents with painful…
Abstract Number: 1333 • ACR Convergence 2022
Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry
William Nowell¹, Shilpa Venkatachalam², Kelly Gavigan¹, Michael George³, Johanna Withers⁴, Laura Stradford⁵, Esteban Rivera¹ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Scipher Medicine Corportaion, Waltham, MA, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although patients' (pts) perspective on disease-related lab testing and its role in treatment decision-making has been examined for some chronic illnesses, ranging from diabetes…
Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Ivone Kim, Debra Ryan, Carmen Cheng and Cindy Kortepeter, Food and Drug Administration, Silver Spring, MD
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…
Abstract Number: 1378 • ACR Convergence 2022
Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort
Ha-Seul Jeoung¹, Kuan Liu¹, Roberta Berard², Wes Fidler³, Janet Pope⁴, Johannes Roth⁵, Carter Thorne⁶, Earl Silverman⁷ and Deborah Levy⁸, ¹University of Toronto, Toronto, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³St. Joseph's Hospital, Thunder Bay, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Ottawa, Ottawa, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill…
Abstract Number: 1280 • ACR Convergence 2022
Patients with Systemic Lupus Erythematosus Perceive the Quality of Care They Receive to Be Suboptimal
Sidha Sreedharan¹, Geoffrey Littlejohn², Russell Buchanan³, Mandana Nikpour⁴, Eric Morand⁵, Alberta Hoi⁶ and Vera Golder⁷, ¹Monash Health, North Melbourne, Australia, ²OPAL Rheumatology Ltd, Melbourne, Australia, ³Austin Health, Heidelberg, Australia, ⁴The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ⁵Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ⁶Monash Health, Melbourne, Australia, ⁷Monash University, Clayton, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease associated with frequent healthcare interactions. The Chronic Care Model is a widely accepted framework…
Abstract Number: 1342 • ACR Convergence 2022
Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients
Reid Weisberg¹, Brett Capel¹, Annabelle Guo¹, Komal Patel¹, Rashmi Arora², Swathi Reddy³ and Una Makris⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Dallas VA Medical Center / University of Texas Southwestern Medical Center, Dallas, TX, ³Dallas VA Medical Center / University of Texas Southwestern Medical Center, Colleyville, TX, ⁴UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: In September 2021, the FDA updated its boxed warnings for Janus Kinase (JAK) inhibitors to include increased risk of major adverse cardiac events (MACE)…
Abstract Number: 1389 • ACR Convergence 2022
The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
Patrick Garnero¹, Evelyne Gineyts¹, Jean-Charles Rousseau¹, Pascal Richette², Jérémie SELLAM³ and Roland Chapurlat¹, ¹INSERM 1033, Lyon, France, ²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France
Background/Purpose: The prognosis of rheumatoid arthritis (RA) is highly variable across patients (P.) and difficult to predict. Usual risk factors, e.g., radiological joint damage, increased…
Abstract Number: 1374 • ACR Convergence 2022
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
Jordan Roberts¹, Mindy Lo¹, Rebecca Sadun², Emily Smitherman³, Scott Wenderfer⁴ and Mary Beth F. Son¹, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Duke University, Durham, NC, ³University of Alabama at Birmingham, Birmingham, AL, ⁴British Columbia Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Belimumab is the only targeted therapy approved for pediatric systemic lupus erythematosus (pSLE), although use remains limited in children. While clinical trials and studies…
Abstract Number: 1269 • ACR Convergence 2022
Implementing RAPID-3 Using Electronic Patient Portal and Point of Care Entry
Sancia Ferguson¹, Lori Zemlicka², Amanda Weber², Abdul Halabi³, Jon Arnason⁴ and Christie Bartels⁵, ¹University of Wisconsin School of Medicine & Public Health, Madison, WI, ²UW Health, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴University of Wisconsin Hospitals and Clinics, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: The treat-to-target approach endorsed by the ACR for rheumatoid arthritis requires frequent monitoring of disease activity using validated instruments, with changes to the treatment…
Abstract Number: 1385 • ACR Convergence 2022
Clinical and Serologic Characterization of Juvenile Systemic Sclerosis Overlap Disease
Amanda Robinson and Kathryn Torok, Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a systemic fibroinflammatory autoimmune disease characterized by skin fibrosis and multiple extracutaneous manifestations. A proportion of children with jSSc…
Abstract Number: 1353 • ACR Convergence 2022
Dietary Practices and Beliefs of Patients with Rheumatic Diseases and Relationship with Symptoms: Results of a Multicenter Cross-sectional Study
Domitille RENARD¹, Sophie Tuffet², Philippe Dieude³, Pascal Claudepierre⁴, Laure Gossec⁵, Bruno Fautrel⁶, Anna Molto⁷, Corinne MIceli⁸, Pascal Richette⁹, Emmanuel Maheu¹⁰, Claire Carette¹¹, Sebastien Czernichow¹¹, Chloe JAMAKORZYAN¹², alexandra Rousseau², Francis Berenbaum¹³, Catherine Beauvais¹⁴ and Jérémie SELLAM¹⁵, ¹Sorbonne University Paris- Sant Antoine Hospital, Paris, France, ²Saint Antoine hospital, Paris, Ile-de-France, France, ³Université Paris Cité, Paris, France, ⁴Paris Est Creteil University, Creteil, France, ⁵Sorbonne Université, Paris, France, ⁶Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁷Rheumatology Department, Cochin Hospital, APHP, Paris, France, ⁸APHP, Paris, France, ⁹Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹⁰Hôpital Paris Saint Antoine, Moirans, Auvergne-Rhône-Alpes, France, ¹¹Hôpital Européen Georges Pompidou, Paris, France, ¹²Hopital Begin, Saint-Mandé, France, ¹³Sorbonne University - Saint-Antoine hospital, Paris, France, ¹⁴Saint Antoine hospital, Paris, France, ¹⁵Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France
Background/Purpose: Diet is a subject of questioning and beliefs among patients with rheumatic diseases. They are inclined to change their eating habits and sometimes follow…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].